Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Conditions
Brief summary
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Erlotinib hydrochloride may also make tumor cells more sensitive to radiation therapy. Radiation therapy uses high-energy x- rays and other types of radiation to kill tumor cells. Giving erlotinib hydrochloride together with radiation therapy may be an effective treatment for patients with head and neck cancer.PURPOSE: This phase II trial is studying how well giving erlotinib hydrochloride together with radiation therapy works in treating patients with stage III-IV squamous cell cancer of the head and neck.
Detailed description
PRIMARY OBJECTIVES:I. To determine the time to progression of the combination of the EGFR inhibitor erlotinib and radiation therapy. SECONDARY OBJECTIVES:I. To determine objective response rate, locoregional control rate, duration of response, patterns of failure, overall survival, toxicities and quality of life outcomes of the combination of erlotinib and concurrent radiation therapy.II. To determine the pharmacokinetic profile of erlotinib. Additional analyses of the pharmacokinetic data on patients receiving daily erlotinib treatment via their feeding tube will be conducted. III. To determine the effect of treatment and dose of treatment on biologic correlates in tumor tissue and/or surrounding mucosa, EGFR expression and phosphorylation status, serum markers of angiogenic activity VEGF, sVEGFR-2, sKIT, ICAM, PDGF, fluorescence in situ hybridization (FISH) for ERBB2 for gene amplification, DNA-sequencing of EGFR and ERBB2 genes from DNA extracted from pretreatment biopsy material for mutation screening, gene expression profiling on pre-treatment biopsy material to identify predictors of response to treatment, apoptosis (TUNEL assay), Ki67 (nuclear proliferation antigen)IV. To determine the utility of the comprehensive geriatric assessment, in predicting tolerance to treatment in patients \>= 65 years included in this trial. OUTLINE: Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.After completion of study treatment, patients are followed up at 6 months, every 3 months for 2 years, and then every 6 months for 2 years.
Interventions
DRUGerlotinib hydrochloride
Given orally or via gastronomy tube
RADIATIONintensity-modulated radiation therapy
IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
OTHERpharmacogenomic studies
Optional correlative studies
OTHERgene expression analysis
Correlative studies
RADIATION3-dimensional conformal radiation therapy
The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks. The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field.
OTHERbiopsy
Optional correlative studies
OTHERpharmacological study
Optional correlative studies
OTHERlaboratory biomarker analysis
Optional correlative studies
OTHERquestionnaire administration
Optional ancillary studies
OTHERenzyme-linked immunosorbent assay
Optional correlative studies
OTHERpolymorphism analysis
Optional correlative studies
Sponsors
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed locally advanced (stage III or IV) squamous cell carcinoma of the head and neck without distant metastatic disease, who are not candidates or have declined definitive surgical resection or for administration of standard chemotherapy during radiation therapy because of any of the following reasons: advanced age (\>= 70 years); poor ECOG performance status (2 or 3); significant comorbidities, as reflected by a Charlson comorbidity index score of \>= 3; abnormal hematopoietic, hepatic or renal function; patient's decision after applicable standard treatment options have been offered and declined by patient * No prior chemotherapy, radiation therapy, or investigational antitumor drug * Measurable disease within 4 weeks prior to registration according to the recommended RECIST response criteria * Life expectancy of greater than 12 weeks * Patients must have normal hepatic function or well compensated liver disease as defined by the Child-Pugh classification of severity of liver disease; patients with hepatic impairment (total bilirubin greater than upper limit of normal \[ULN\] or well-compensated disease \[Child-Pugh class A\] enrolled in the trial will be closely monitored, especially those with total bilirubin \> 3 times ULN; dosage modifications (therapy interruption or discontinuation) may be necessary for severe changes in liver function; patient management will follow the FDA-approved labeling recommendations * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation * Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter * Women of childbearing potential must have a negative pregnancy test; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and willingness to sign a written informed consent document
Exclusion criteria
* All histologies other than squamous cell carcinoma * Salivary gland paranasal sinus and nasopharyngeal squamous cell carcinoma * Patients who have had prior chemotherapy or radiotherapy * Patients with metastatic disease * Patients with ECOG performance status of 4 * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ERLOTINIB * Patients with history of any other malignancy (except squamous cell or basal cell cancer of the skin or CIS of cervix) are ineligible unless a period of 5 years has elapsed since treatment of the previous cancer and the patient is currently disease-free from the previous cancer * Patients may not be receiving any other investigational agent * Pregnant women; breastfeeding should be discontinued
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Disease Progression | 1 year and 10 months following study start | The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started. Disease progression free survival (PFS) is measured from start of treatment to the date of disease progression or protocol-designated outcome, whichever occurs first and censored at the date of last followed for those survivors without disease progression Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Measured via Conventional CT and MRI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | 1 year and 10 months following study start | Number of patients with complete response, partial response, stable disease, or progressive disease. Assessed via Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Measured via conventional CT and MRI |
| Patterns of Failure | 5 yrs following treatment | — |
| Toxicities, Number of Persons With Adverse Events | up to 2 yrs after treatment | Number of participants who experienced adverse events (AE's) and serious adverse events (SAE's) during the course of the trial according to CTCAE (4.0) |
| Quality of Life Assessment as Measured by Functional Assessment of Cancer Therapy (FACT-G) Test | after treatment at 6 mos | Quality of Life (QOL) measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. |
| Locoregional Control Rate | 5 yrs following treatment | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic Data | pre-treatment then weekly | Determine the pharmacokinetic profile of erlotinib. Additional analyses of the pharmacokinetic data on patients receiving daily erlotinib treatment via their feeding tube will be conducted. |
| Lab Correlates | 2 yrs post concurrent chemo-radiation therapy | Determine the effect of treatment and dose of treatment on biologic correlates in tumor tissue and/or surrounding mucosa. |
Countries
United States
Participant flow
Recruitment details
Patients recruited from local medical clinic from January 2011 through May 2012.
Participants by arm
| Arm | Count |
|---|---|
| Arm I Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. | 2 |
| Total | 2 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lack of Efficacy | 1 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Arm I |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants |
| Region of Enrollment United States | 2 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 2 / 2 |
| serious Total, serious adverse events | 1 / 2 |
Outcome results
Primary
Time to Disease Progression
The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started. Disease progression free survival (PFS) is measured from start of treatment to the date of disease progression or protocol-designated outcome, whichever occurs first and censored at the date of last followed for those survivors without disease progression Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Measured via Conventional CT and MRI
Time frame: 1 year and 10 months following study start
Population: One patient progressed while study was still active, study closed before follow up completed for second participant and therefore was not evaluable.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I | Time to Disease Progression | 6 months |
Secondary
Locoregional Control Rate
Time frame: 5 yrs following treatment
Population: Due to the low accrual no data collected.
Secondary
Objective Response Rate
Number of patients with complete response, partial response, stable disease, or progressive disease. Assessed via Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Measured via conventional CT and MRI
Time frame: 1 year and 10 months following study start
Population: One patient progressed while study was still active, study closed before follow up completed for second participant and therefore was not evaluable.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm I | Objective Response Rate | Partial response | 1 Participants |
| Arm I | Objective Response Rate | Complete response | 0 Participants |
| Arm I | Objective Response Rate | Stable disease | 0 Participants |
| Arm I | Objective Response Rate | Progressive disease | 0 Participants |
Secondary
Patterns of Failure
Time frame: 5 yrs following treatment
Population: Participants did not complete follow-up per protocol as trial was terminated early
Secondary
Quality of Life Assessment as Measured by Functional Assessment of Cancer Therapy (FACT-G) Test
Quality of Life (QOL) measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL.
Time frame: after treatment at 6 mos
Population: QOL was no collected and analyzed for this study due to study termination.
Secondary
Toxicities, Number of Persons With Adverse Events
Number of participants who experienced adverse events (AE's) and serious adverse events (SAE's) during the course of the trial according to CTCAE (4.0)
Time frame: up to 2 yrs after treatment
Population: Participants enrolled in trial and given treatment. See AE section for details.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm I | Toxicities, Number of Persons With Adverse Events | 2 Participants |
Other Pre-specified
Lab Correlates
Determine the effect of treatment and dose of treatment on biologic correlates in tumor tissue and/or surrounding mucosa.
Time frame: 2 yrs post concurrent chemo-radiation therapy
Population: Both participants did not complete treatment per protocol and were not evaluable. No data collected.
Other Pre-specified
Pharmacokinetic Data
Determine the pharmacokinetic profile of erlotinib. Additional analyses of the pharmacokinetic data on patients receiving daily erlotinib treatment via their feeding tube will be conducted.
Time frame: pre-treatment then weekly
Population: Both participants did not complete treatment per protocol and were not evaluable. No data collected.